NASDAQ:LXRX Lexicon Pharmaceuticals Q3 2025 Earnings Report $1.42 -0.05 (-3.40%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.42 0.00 (0.00%) As of 10/17/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Lexicon Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.07Beat/MissN/AOne Year Ago EPSN/ALexicon Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$5.81 millionBeat/MissN/AYoY Revenue GrowthN/ALexicon Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/11/2025TimeBefore Market OpensConference Call DateTuesday, November 11, 2025Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Lexicon Pharmaceuticals Earnings HeadlinesLexicon Pharmaceuticals, Inc. (LXRX) Presents at Arrowhead's 19th Annual Pain Therapeutics Summit - SlideshowOctober 15 at 7:03 PM | seekingalpha.comLexicon presents additional pilavapadin data in DPNPOctober 14, 2025 | msn.comTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-changing system designed to replace income taxes and send direct payouts to everyday Americans. More than $1 TRILLION is expected to be distributed... and YOU could be eligible to claim a massive check. | Angel Publishing (Ad)Lexicon Pharmaceuticals: Promising Phase 2b Results and Strategic Plans Justify Buy RatingOctober 14, 2025 | tipranks.comLexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics SummitOctober 14, 2025 | globenewswire.comLexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain ManagementOctober 8, 2025 | quiverquant.comQSee More Lexicon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexicon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexicon Pharmaceuticals and other key companies, straight to your email. Email Address About Lexicon PharmaceuticalsLexicon Pharmaceuticals (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases. The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy. In addition to this marketed asset, Lexicon maintains a diversified pipeline with programs spanning metabolic diseases, neuropathic pain, and rare genetic disorders. Key development candidates include small-molecule inhibitors modulating glucose transport and neuroreceptor activity, each designed to address unmet medical needs through precise mechanism-based intervention. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals has been publicly traded on the NASDAQ exchange since 2000. The company collaborates with academic institutions, strategic partners and patient advocacy groups to advance its research and expand clinical development globally. With a core scientific team experienced in genomics, medicinal chemistry and clinical development, Lexicon continues to pursue innovative solutions aimed at improving patient outcomes across a variety of therapeutic areas.View Lexicon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings Intuitive Surgical (10/21/2025)Nasdaq (10/21/2025)Netflix (10/21/2025)Texas Instruments (10/21/2025)Citigroup (10/21/2025)Chubb (10/21/2025)Capital One Financial (10/21/2025)Danaher (10/21/2025)Elevance Health (10/21/2025)GE Aerospace (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
